Summary
Although protein kinase C has been shown to be involved in a wide range of biological functions, the precise role of each isoform in a specific cell function remains to be clarified. Here we demonstrate that a ribozyme specific for the human protein kinase Cα (PKCα), a classical PKC isoform, induces cell death in glioma cell lines. This cell death was identified as apoptosis by morphologic alterations and endonucleosomal DNA fragmentation. The inhibition of PKCα gene expression by the ribozyme resulted in a significant reduction in Bcl-xL gene expression, a protein that inhibits apoptosis and is overexpressed in glioma cells. Taken together, our data suggest that the PKCα ribozymes are a potent inducer of apoptosis in glioma cells, which may act through suppressing Bcl-xL gene expression and/or activity. PKCα ribozymes may prove useful in the management of malignant gliomas.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Blobe, G. C., Obeid, L. M. & Hannun, Y. A. (1994). Regulation of protein kinase C and role in cancer biology. Cancer Met Rev 13: 411–431.
Cameron, F. H. & Jennings, P. A. (1989). Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci USA 83: 8859–8862.
Caponigro, F., French, R. C. & Kaye, S. B. (1997). Protein kinase C: a worthwhile target for anticancer drugs? Anti-Cancer Drugs 8: 26–33.
Chomczynski, P. & Sacchi, N. (1987). Single step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. Anal Biochem 162: 156–159.
Cotten, M. & Birnstiel, M. L. (1989). Ribozyme mediated destruction of RNA in vivo. EMBO J 8: 3861–3866.
Couldwell, W. T., Hinton, D. R., He, S., Chen, T. C., Sebat, I., Weiss, M. H. & Law, R. E. (1994). Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43–46.
Couldwell, W. T., Uhm, J. H., Antel, J. P. & Young, V. W. (1991). Enhanced protein kinase C activity with the growth rate of malignant gliomas in vitro. Neurosurgery 29: 880–887.
Dean, N., McKay, R., Miraglia, L., Howard, R., Cooper, S., Giddings, J., Nicklin, P., Meister, L., Ziel, R., Geiger, T., Muller, M. & Fabbro, D. (1996). Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res 56: 3499–3507.
Dekker, L. V. & Parker, P. J. (1994). Protein kinase C: a question of specificity. TIBS 19: 73–77.
Haseloff, J. & Gerlach, W. L. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334: 585–591.
Hertel, K. J., Pardi, A., Uhlenbeck, O. L., Koizumi, M., Ohtsuka, E., Vesugi, S., Cedergren, R., Eckstein, F. & Gerlach, W. L. (1992). Numbering system for the hammerhead. Nucleic Acids Res 20: 3252
Ikemoto, H., Tani, E., Matsumoto, T., Nakano, A. & Furuyama, J. I. (1995). Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J Neurosurg 83: 1008–1016.
Kroemer, G. (1997). The prot-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614–620.
Meggio, F., Donnella-Deana, A., Ruzzene, M., Brunati, A. M., Cesaro, L., Buerra, B., Meyer, T., Mett, H., Fabbro, D., Furet, P., Dobrowolksa, G. & Pinna, L. A. (1995). Different susceptibility of protein kinases to staurosporine inhibition: kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem 234: 317–322.
Min, A. J., Rudin, C. M., Boise, L. H. & Thompson, C. B. (1995). Expression of Bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903–1910.
Mischak, H., Goodnight, J., Kolch, W., Martiny-Baron, G., Schaechtle, C., Kazanietz, M. G., Blumberg, P. M., Pierce, J. H. & Mushinski, J. F. (1993). Overexpression of protein kinase C-δ and -ɛ in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorgenicity. J Biol Chem 268: 6090–6096.
Newton, A. C. (1995). Protein kinase C: structure, function, and regulation. J Biol Chem 270: 28495–28498.
Nishizuka, Y. (1992). Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607–614.
Parker, P., Kour, G., Marais, R., Mitchell, F., Pears, C., Stabel, S. & Webster, C. (1989). Protein kinase C a family affair. Mol Cell Endocrinol 65: 1–11.
Pegoraro, L., Palumbo, A., Erikson, J., Falda, M., Giovanazzo, B., Emanuel, B. S., Rovero, G., Nowell, P. C. & Croce, C. M. (1984). A 14;18 and a 8;14 chromosome translocation in a cell line derived from an acute B cell leukemia. Proc Natl Acad Sci USA 81: 7166–7170.
Qiao, L., Koutsos, M., Tsai, L. L., Kozoni, V., Guzman, J., Shiff, S. J. & Rigas, B. (1996). Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT-29 human colon adenocarcinoma cells. Cancer Lett 107: 83–89.
Rodin, C. M. & Thompson, C. B. (1997). Apoptosis and disease. Annu Rev Med 48: 267–281.
Ruvolo, P. P., Deng, X., Carr, B. K. & May, W. S. (1998). A functional role for mitochondrial protein kinase Cα in Bcl-2 phosphorylation and suppression of apoptosis. J Biol Chem 273: 25436–25442.
Sarver, N., Cantin, E. M., Chang, P. S., Zaia, J. A., Ladne, P. A., Stephens, D. A. & Rossi, J. J. (1990). Ribozymes as potential anti HIV-1 therapeutic agents. Science 247: 1222–1225.
Scanlon, K. J., Ishida, H. & Kashani-Sabet, M. (1994). Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci USA 91: 11123–11127.
Sioud, M. (1994). Interaction between tumor necrosis factor α ribozyme and cellular proteins. J Mol Biol 242: 619–629.
Sioud, M. (1996). Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-α production by peritoneal cells in vitro and in vivo. Eur J Immunol 26: 1026–1031.
Sioud, M. & Drlica, K. (1991). Prevention of HIV-1 integrase expression in E coli by a ribozyme. Proc Natl Acad Sci USA 88: 7303–7307.
Sioud, M. & Jespersen, L. (1996). Enhancement of hammerhead ribozyme catalysis by glyceraldehyde-3-phosphate dehydrogenase. J Mol Biol 257: 775–789.
Sioud, M. & Sørensen, D. R. (1998). A nuclease-resistant protein kinase Cα ribozyme blocks glioma cell growth. Nature Biotech 16: 556–561.
Sioud, M., Natvig, J. B. & Førre, Ø (1992). Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J Mol Biol 223: 831–835.
Whelan, R. D. H. & Parker, P. J. (1998). Loss of protein kinase C function induces an apoptotic response. Oncogene 16: 1939–1944.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Leirdal, M., Sioud, M. Ribozyme inhibition of the protein kinase Cα triggers apoptosis in glioma cells. Br J Cancer 80, 1558–1564 (1999). https://doi.org/10.1038/sj.bjc.6690560
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690560
Keywords
This article is cited by
-
Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia
Medical Oncology (2013)
-
Mitochondrial anchoring of PKCα by PICK1 confers resistance to etoposide-induced apoptosis
Apoptosis (2007)
-
Combination of E of Enddostatin and a Protein Kinase Cα DNA Enzyme Improves the Survival of Rats with Malignant Glioma
Neoplasia (2002)
-
Protein kinase C inhibitors
Current Oncology Reports (2002)